Rxo (RXO) Equity Average (2021 - 2026)

Rxo (RXO) has 6 years of Equity Average data on file, last reported at $1.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 4.66% year-over-year to $1.5 billion; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (down 4.66% YoY), and the FY2025 full-year result was $1.6 billion, up 42.93% from the prior year.
• Equity Average for Q1 2026 stood at $1.5 billion, down from $1.6 billion in the prior quarter.
• Across five years, Equity Average topped out at $1.6 billion in Q4 2024 and bottomed at $580.5 million in Q2 2024.
• The 5-year median for Equity Average is $1.1 billion (2024), against an average of $1.1 billion.
• The widest annual swing landed in 2023, when Equity Average tumbled 49.68%; it then jumped 175.68% in 2024.
• A 5-year view of Equity Average shows it stood at $865.5 million in 2022, then plunged by 31.6% to $592.0 million in 2023, then soared by 175.68% to $1.6 billion in 2024, then fell by 4.38% to $1.6 billion in 2025, then decreased by 2.27% to $1.5 billion in 2026.
• The last three Equity Average figures came in at $1.5 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.

Peer Comparison